Future oncology最新文献_第7页

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. rechARge：雄激素受体配体定向降降剂BMS-986365与研究者选择的mCRPC患者的随机III期试验

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-06-02 DOI: 10.1080/14796694.2025.2502318

Kim Nguyen Chi, Rana R McKay, Shahneen Sandhu, Jose A Arranz, Philippe Barthélémy, Boris Hadaschik, Nobuaki Matsubara, Neal D Shore, Dingwei Ye, Teresa Cascella, Irina Irincheeva, Stephanie Kreiser, Antoine Thiery-Vuillemin, Dana E Rathkopf

{"title":"rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.","authors":"Kim Nguyen Chi, Rana R McKay, Shahneen Sandhu, Jose A Arranz, Philippe Barthélémy, Boris Hadaschik, Nobuaki Matsubara, Neal D Shore, Dingwei Ye, Teresa Cascella, Irina Irincheeva, Stephanie Kreiser, Antoine Thiery-Vuillemin, Dana E Rathkopf","doi":"10.1080/14796694.2025.2502318","DOIUrl":"10.1080/14796694.2025.2502318","url":null,"abstract":"There is an ongoing need for efficacious, life-prolonging therapies for males with metastatic castration-resistant prostate cancer (mCRPC). mCRPC that progresses after treatment with androgen receptor pathway inhibitors (ARPIs) may still be driven by AR signaling. BMS-986365 is a heterobifunctional, orally bioavailable ligand-directed degrader that targets the AR through a first-in-class dual mechanism of AR degradation and antagonism. Here, we present the study design of rechARge, a phase III, randomized, multicenter, adaptive, two-part, open-label trial evaluating BMS-986365 versus investigator's choice of therapy comprising either docetaxel or a switch to an alternative ARPI (abiraterone or enzalutamide) in patients with mCRPC whose disease has progressed after treatment with one prior ARPI. The primary study objective is to compare the efficacy and safety of BMS-986365 versus investigator's choice of therapy. Approximately 960 patients will be enrolled.Clinical trial registration: www.clinicaltrials.gov identifier is NCT06764485.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1771-1777"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide. 一项使用HapMap细胞系的全基因组关联研究揭示了细胞对环磷酰胺反应的调节因子。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-13 DOI: 10.1080/14796694.2025.2501517

Mohammed O Gbadamosi, Neha Bhise, Taraswi Mitra Ghosh, Elizabeth K Molchan, Kathleen Streeks, Jason Puglise, Alyssa Ohaegbulam, Mariana Makarem, Oluwaseyi Olabige, Changlin Yang, Luisel Ricks-Santi, Duane A Mitchell, Brooke L Fridley, Jatinder K Lamba

{"title":"A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide.","authors":"Mohammed O Gbadamosi, Neha Bhise, Taraswi Mitra Ghosh, Elizabeth K Molchan, Kathleen Streeks, Jason Puglise, Alyssa Ohaegbulam, Mariana Makarem, Oluwaseyi Olabige, Changlin Yang, Luisel Ricks-Santi, Duane A Mitchell, Brooke L Fridley, Jatinder K Lamba","doi":"10.1080/14796694.2025.2501517","DOIUrl":"10.1080/14796694.2025.2501517","url":null,"abstract":"Aims: This study identifies single-nucleotide polymorphisms (SNPs) associated with cellular response to cyclophosphamide (CTX) using phosphoramide mustard (PM), its primary cytotoxic metabolite, and explores the downstream consequences for breast cancer (BC) patients.Methods: We analyzed 1,978,545 SNPs from EBV-transformed lymphoblastic cell lines (LCLs) derived from 53 unrelated European individuals, in a genome-wide association study using cellular PM sensitivity data. We filtered SNPs associated with PM sensitivity (p < 5 × 10-5) predicted to overlap with regulatory elements in breast tissue using a chromatin state prediction model. We then assessed the consequences using LCL transcriptomic data and data from BC patients treated with (ACT-BC; N = 155) and without CTX.Results: Twenty SNPs were filtered out including rs12408401, which was associated with PM resistance (p = 3.89 × 10-5), potentially disrupted a CTCF-loop, and was associated with increased RFX5 expression (p = 0.036), which was associated with poor disease-free interval in ACT-BC patients (HR = 5.32; p = 0.028); and rs784562, which was associated with improved PM sensitivity (p = 6.41 × 10-6), potentially altered nearby enhancer functionality, and reduced expression of KRT72 which was associated with poor progression-free survival in ACT-BC patients (HR = 3.61; p = 0.040).Conclusion: Our study identifies SNPs significantly associated with cellular CTX response with potential mechanistic and clinical relevance, thereby providing insights toward optimized CTX treatment strategies.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1809-1822"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings. 多发性骨髓瘤的护理，治疗模式，和治疗持续时间在学术和社区护理设置。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-21 DOI: 10.1080/14796694.2025.2504318

Natalie Boytsov, Catherine B McGuiness, Zifan Zhou, Tianyao Huo, Kathleen Montgomery, Nirali Kotowsky, Chi-Chang Chen

{"title":"Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings.","authors":"Natalie Boytsov, Catherine B McGuiness, Zifan Zhou, Tianyao Huo, Kathleen Montgomery, Nirali Kotowsky, Chi-Chang Chen","doi":"10.1080/14796694.2025.2504318","DOIUrl":"10.1080/14796694.2025.2504318","url":null,"abstract":"Aim: Evaluate multiple myeloma (MM) treatment patterns, healthcare utilization (HCRU), and costs from academic and community settings.Methods: This observational study linked US MM insurance claims (1 April 2017-30 June 2022) with provider affiliations to evaluate patient characteristics and treatment durations across patient cohorts defined by care setting of treatment (academic only, community only, mixed [both]), as well as treatment patterns, HCRU, and costs of care (e.g. treatment, office visits, hospitalization) in each setting.Results: 3778 patients were included. By cohort (n = 530 academic; n = 1647 community), the community cohort was older with more comorbidities. Mixed-cohort patients (n = 1601) frequently initiated treatment at community centers and briefly shifted to academic centers for transplant. Among 3778 patients who received MM-related care, most claims were from the community setting. The academic setting had high rates of claims for proteasome inhibitors (56.3% of patients) and steroids (52.5%); the community setting had high rates for immunomodulatory drugs (75.1%) and steroids (85.0%). Stem cell transplant claims were more common for academic versus community (21.4%/7.3%). Treatment duration/time to next therapy were similar between cohorts. Costs were generally higher in the academic versus community settings.Conclusion: Improved patient support is needed in community settings, where most MM care occurs.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1905-1918"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma. 美国转移性去分化脂肪肉瘤患者的真实生存结果和MDM2患病率。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-06-04 DOI: 10.1080/14796694.2025.2502319

Steven Robinson, Alyssa B Klein, Stephen A Stanhope, Kathryn Evans, Mark Agulnik

{"title":"Real-world survival outcomes and MDM2 prevalence in US patients with metastatic dedifferentiated liposarcoma.","authors":"Steven Robinson, Alyssa B Klein, Stephen A Stanhope, Kathryn Evans, Mark Agulnik","doi":"10.1080/14796694.2025.2502319","DOIUrl":"10.1080/14796694.2025.2502319","url":null,"abstract":"Background: Limited data exist regarding dedifferentiated liposarcoma (DDLPS) treatment, biomarker frequency, and clinical outcomes. Additional epidemiological data are needed to inform clinical trial design for testing novel therapeutics.Materials and methods: Retrospective data from a US-based deidentified clinico-genomic database were analyzed for patients treated for metastatic DDLPS between 2011 and 2021.Results: Overall survival (OS), real-world progression-free survival (rwPFS), and time to next treatment (TTNT) were described in the overall cohort (n = 51) and in a subgroup of patients with murine double minute 2 (MDM2) amplification and wild-type tumor protein p53 (TP53 WT) (n = 38, 74.5%). Patients had a median age of 64.8 years, and 62.7% were male. The most common first-line treatment was doxorubicin with olaratumab (23.5%). From time of first-line (1 L) treatment, median OS for the entire cohort and MDM2-amplified, TP53 WT subgroup was 12.6 and 11.7 months, respectively; median rwPFS was 2.5 months for both. Median TTNT was 3.9 months for the full cohort and 4.8 months for the MDM2-amplified, TP53 WT subgroup.Conclusions: The descriptive analysis here contributes real-world data describing treatment patterns, biomarker status, and clinical outcomes for patients with DDLPS, an aggressive and poorly characterized form of LPS with limited treatment options.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1797-1807"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research progress on monocyte/macrophage in the development of gastric cancer. 单核/巨噬细胞在胃癌发生发展中的研究进展。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-12 DOI: 10.1080/14796694.2025.2504334

Yuan-Kun Gou, Jie Zhou, Peng Liu, Ming-Yi Wang

引用次数: 0

Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma. 替拉替尼治疗189例r/r原发性中枢神经系统淋巴瘤的上市后监测

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-27 DOI: 10.1080/14796694.2025.2507561

Akira Kawasaki, Ichiro Matsumoto, Koji Izutsu, Ryo Nishikawa

{"title":"Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma.","authors":"Akira Kawasaki, Ichiro Matsumoto, Koji Izutsu, Ryo Nishikawa","doi":"10.1080/14796694.2025.2507561","DOIUrl":"10.1080/14796694.2025.2507561","url":null,"abstract":"Background: This post-marketing surveillance evaluated the safety and effectiveness of tirabrutinib in patients with relapsed/refractory primary central nervous system lymphoma (r/r PCNSL) in a real-world setting in Japan.Methods: All patients with r/r PCNSL who started treatment with tirabrutinib between May 20 and 31 October 2020, were registered. Adverse drug reactions (ADRs) and effectiveness were assessed over 52-weeks from the start of tirabrutinib treatment.Results: Of the 189 patients assessed for safety, 52.4% were male, the median age was 70.0 years (range 30-88), and 49.2% of patients had a Karnofsky performance status score of ≤60. ADRs of any grade and grade ≥3 were observed in 55.6% and 24.3% of patients, respectively. The most common ADRs were rash (11.6%), neutrophil (10.1%) and platelet (5.3%) count decreased. Most of the ADRs corresponding to infections, clinically significant skin disorders, myelosuppression, hypersensitivity, interstitial lung diseases, hepatic function disorders, and hemorrhages resolved or were in the process of resolving. Among the 121 patients assessed for effectiveness, the overall response rate evaluated by the treating physicians was 61.2%, and the 365-day survival rate was 69.8%.Conclusion: This surveillance confirmed the tolerability and effectiveness of tirabrutinib in patients with r/r PCNSL in the real-world setting.Clinical trial registration: Japan Registry of Clinical Trials: jRCT2011210002.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1837-1847"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of postmastectomy radiotherapy after neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis. 乳腺癌患者新辅助化疗后乳房切除术放疗的效果：一项荟萃分析。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-06-02 DOI: 10.1080/14796694.2025.2505372

Aishan Zou, Liuyi Li, Yang Guo, Cuiwei Zhang

{"title":"The effect of postmastectomy radiotherapy after neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis.","authors":"Aishan Zou, Liuyi Li, Yang Guo, Cuiwei Zhang","doi":"10.1080/14796694.2025.2505372","DOIUrl":"10.1080/14796694.2025.2505372","url":null,"abstract":"Background: Recent advancements in NAC efficacy have sparked considerable debate regarding the role of postmastectomy radiation therapy (PMRT) in breast cancer treatment.Methods: A comprehensive search of PubMed, Embase, and Cochrane databases was conducted to identify all relevant studies examining the prognostic significance of PMRT in breast cancer patients. The incidence of adverse events was aggregated to determine the correlation between PMRT and patient survival outcomes.Results: The current meta-analysis included 15 eligible studies. Patients who received PMRT numbered 42,289, while 23,199 did not receive these treatments. No significant difference was observed between PMRT and OS (pooled RR 0.93; 95% CI 0.83-1.04) or DMFS (pooled RR 1.12; 95% CI 0.99-1.28) in predicting breast cancer outcomes. PMRT was associated with improved DFS in patients with lymphovascular invasion (LVI) (pooled RR 0.33; 95% CI 0.19-0.57). The meta-analysis found no significant correlation between PMRT and OS in patients with pathological complete remission (pCR) (HR 0.86; 95% CI 0.68-1.07).Conclusion: No significant difference was observed between PMRT and OS. While PMRT did not improve overall survival in the entire group, our subgroup analyses suggest selective benefit for non-pCR or LVI positive patients. These findings may aid in the clinical decision-making process.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1929-1938"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy. 合并症对接受免疫治疗的老年癌症患者免疫相关不良事件和生存的影响

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-27 DOI: 10.1080/14796694.2025.2502313

Alyssa A Guo, Mary-Peyton Knapp, Joni K Evans, Andrew T Faucheux, Sarah N Price, Heidi D Klepin, Beverly Levine, Alexander Quattlebaum, Chance Bloomer, Lara Khoury, John C Hunting, Catherine A Elko, Eric Olson, Thomas W Lycan

{"title":"Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy.","authors":"Alyssa A Guo, Mary-Peyton Knapp, Joni K Evans, Andrew T Faucheux, Sarah N Price, Heidi D Klepin, Beverly Levine, Alexander Quattlebaum, Chance Bloomer, Lara Khoury, John C Hunting, Catherine A Elko, Eric Olson, Thomas W Lycan","doi":"10.1080/14796694.2025.2502313","DOIUrl":"10.1080/14796694.2025.2502313","url":null,"abstract":"Background: Nearly half of patients with cancer are diagnosed at 70 years or older, which presents challenges in cancer care due to their high comorbidity burden and the underrepresentation of this age group in clinical trials. This retrospective study evaluated the association between comorbidity burden and immune checkpoint inhibitors (ICIs) treatment outcomes among older adults.Methods: Data were collected from patients aged 70 years or older at the time of diagnosis who were treated with ICIs from 2011 to 2022. Key clinical outcomes include changes in performance status, overall survival (OS), progression-free survival (PFS), and immune-related adverse events (irAEs) and were compared between low baseline Charlson Comorbidity Index (CCI) and high CCI (<4 vs. ≥4) groups.Results: Among 1,223 patients, patients with CCI scores ≥4 (n = 300) had a significantly shorter OS (11.4 vs. 13.6 months, p = 0.0461) but similar PFS (8.0 vs. 7.7 months, p = 0.258) compared to patients with CCI scores <4. There was no significant difference in changes in performance status pre- and post-treatment (p = 0.14) or in the irAE prevalence between the two groups (39.3% vs. 38.3%, p = 0.786).Conclusion: Our study suggests that ICIs are safe in patients with high comorbidity burden but that the presence of pre-treatment comorbidities decreases overall survival.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1787-1796"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors-design and rationale. E-VIRTUE：一项联合或不联合派姆单抗治疗罕见泌尿生殖系统肿瘤的研究——设计和原理。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-27 DOI: 10.1080/14796694.2025.2497719

Elias B A Chandran, Saad Atiq, Nicholas Simon, Daniel Girardi, Lisa Ley, Lisa Cordes, Ruchi Patel, Tzu-Fang Wang, Andre R Kydd, Bernadette Redd, Salah Boudjadi, Ian Stukes, Rouf Banday, Elizabeth Smith, Dilara Akbulut, Scot Niglio, Sandeep Gurram, Seth Steinberg, Andrea B Apolo

引用次数: 0

The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summary. 在BREAKWATER研究中，与标准治疗相比，恩科非尼加西妥昔单抗化疗对BRAF v600e突变转移性结直肠癌患者的潜在益处：简单的语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-06-01 Epub Date: 2025-05-20 DOI: 10.1080/14796694.2025.2491290

Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, Cathy Eng, Tae Won Kim, Harpreet Singh Wasan, Jayesh Desai, Fortunato Ciardiello, Rona Yaeger, Timothy S Maughan, Elena Beyzarov, Xiaoxi Zhang, Graham Ferrier, Xiaosong Zhang, Josep Tabernero

引用次数: 0